Calls Now Open
2027 Scholar-Innovator and ADDF-Harrington
April 21, 2026
Harrington Discovery Institute at University Hospitals is now accepting full applications for the 2027 Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants multiple opportunities for funding in addition to expertise from pharma-experienced leaders with a track record of bringing...
Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading
February 08, 2023
In an international, multicenter, pivotal Phase 3 trial, a single under-the-skin injection of a biological drug given to patients within seven days of the onset of COVID-19 symptoms cut the likelihood they needed to be hospitalized in half. Continue Reading
November 22, 2022
Travis Dunckley, PhD, University of Arizona, 2016 ADDF-Harrington Scholar and team have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients. Continue Reading
October 19, 2022
PIC Therapeutics has closed a $35 million Series A financing round centered around the advancement of its lead asset, a novel therapeutic for advanced metastatic breast cancer. Continue Reading
August 18, 2022
Harrington Scholar developing a universal treatment to prevent and treat influenza A. Continue Reading
August 15, 2022
Licensing IP for SIK Inhibitors to Radius Health Continue Reading
August 09, 2022
Development of an exercise wearable to help personalize exercise and minimize the risks of dementia. Continue Reading
April 12, 2022
Potential clinical trial to investigate use in COVID-19 Continue Reading
February 05, 2022
Chiesi Acquires Pioneering Therapeutic Monoclonal Antibodies Portfolio Against EMAP II as Potential Treatment for PAH Continue Reading